Takayasu's arteritis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (13 intermediate revisions by 3 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{FKH}} | {{CMG}} {{AE}} {{FKH}} | ||
==Overview== | |||
Pharmacologic medical therapy is recommended among patients with Takayasu’s arteritis to control [[Inflammation|inflammatory]] process and [[hypertension]]. Pharmacologic medical therapies for include [[Corticosteroid|corticosteroids]], IL-6 receptor inhibitor, B-cell depletion agents, and [[Chemotherapy|cytotoxic drugs]]. | |||
==Medical Therapy== | |||
* Pharmacologic medical therapy is recommended among patients with Takayasu’s arteritis to control [[Inflammation|inflammatory]] process and [[hypertension]].<ref name="pmid12655">{{cite journal |vauthors=Lupi-Herrera E, Sánchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE |title=Takayasu's arteritis. Clinical study of 107 cases |journal=Am. Heart J. |volume=93 |issue=1 |pages=94–103 |date=January 1977 |pmid=12655 |doi= |url=}}</ref><ref name="pmid24097290">{{cite journal |vauthors=Keser G, Direskeneli H, Aksu K |title=Management of Takayasu arteritis: a systematic review |journal=Rheumatology (Oxford) |volume=53 |issue=5 |pages=793–801 |date=May 2014 |pmid=24097290 |doi=10.1093/rheumatology/ket320 |url=}}</ref> | |||
* Pharmacologic medical therapies for include [[Corticosteroid|corticosteroids]], IL-6 receptor inhibitor, B-cell depletion agents, and [[Chemotherapy|cytotoxic drugs]]. | |||
=== Takayasu’s arteritis === | |||
== | * '''1 Corticosteroids''' | ||
** Preferred regimen (1): [[prednisone]] 1 mg/kg PO qd '''(Consider [[osteoporosis]] prevention)''' | |||
* '''2 IL-6 receptor inhibitor''' | |||
** Preferred regimen (1): [[Tocilizumab]] | |||
* '''3 B-cell depletion''' | |||
** Preferred regimen (1): [[Rituximab]] | |||
* '''4 Cytotoxic agents''' | |||
** Preferred regimen (1): [[methotrexate]] | |||
** Preferred regimen (2): [[azathioprine]] | |||
** Preferred regimen (3): [[cyclophosphamide]] | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category: | [[Category:Medicine]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 20:01, 1 May 2018
|
Takayasu's arteritis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Takayasu's arteritis medical therapy On the Web |
|
American Roentgen Ray Society Images of Takayasu's arteritis medical therapy |
|
Risk calculators and risk factors for Takayasu's arteritis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Farnaz Khalighinejad, MD [2]
Overview
Pharmacologic medical therapy is recommended among patients with Takayasu’s arteritis to control inflammatory process and hypertension. Pharmacologic medical therapies for include corticosteroids, IL-6 receptor inhibitor, B-cell depletion agents, and cytotoxic drugs.
Medical Therapy
- Pharmacologic medical therapy is recommended among patients with Takayasu’s arteritis to control inflammatory process and hypertension.[1][2]
- Pharmacologic medical therapies for include corticosteroids, IL-6 receptor inhibitor, B-cell depletion agents, and cytotoxic drugs.
Takayasu’s arteritis
- 1 Corticosteroids
- Preferred regimen (1): prednisone 1 mg/kg PO qd (Consider osteoporosis prevention)
- 2 IL-6 receptor inhibitor
- Preferred regimen (1): Tocilizumab
- 3 B-cell depletion
- Preferred regimen (1): Rituximab
- 4 Cytotoxic agents
- Preferred regimen (1): methotrexate
- Preferred regimen (2): azathioprine
- Preferred regimen (3): cyclophosphamide
References
- ↑ Lupi-Herrera E, Sánchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE (January 1977). "Takayasu's arteritis. Clinical study of 107 cases". Am. Heart J. 93 (1): 94–103. PMID 12655.
- ↑ Keser G, Direskeneli H, Aksu K (May 2014). "Management of Takayasu arteritis: a systematic review". Rheumatology (Oxford). 53 (5): 793–801. doi:10.1093/rheumatology/ket320. PMID 24097290.